Drug Trial Radar · NCT07218809
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Nov 17, 2028
Study completion Dec 27, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation; Ventana Medical Systems, Inc
- First posted
- Oct 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Conditions
- Epithelial Ovarian Cancer
Interventions
AZD5335Drug
antibody drug conjugate
Mirvetuximab Soravtansine (MIRV)Drug
antibody drug conjugate
PaclitaxelDrug
chemotherapy
Pegylated liposomal Doxorubicin (PLD)Drug
chemotherapy
TopotecanDrug
chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free Survival (PFS)Time frame: Up to approximately 5 years
Locations
299 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
Little Rock, Arkansas · Not yet recruiting
Research Site
La Jolla, California · Not yet recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Fort Lauderdale, Florida · Not yet recruiting
Research Site
Gainesville, Florida · Recruiting
Research Site
Jupiter, Florida · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Weston, Florida · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Evanston, Illinois · Not yet recruiting
Research Site
Peoria, Illinois · Recruiting
Research Site
Urbana, Illinois · Recruiting
Research Site
Fort Wayne, Indiana · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Towson, Maryland · Recruiting
Research Site
Burlington, Massachusetts · Recruiting
Research Site
Worcester, Massachusetts · Not yet recruiting
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
Springfield, Missouri · Recruiting
Research Site
Billings, Montana · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
Las Vegas, Nevada · Recruiting
Research Site
Lebanon, New Hampshire · Not yet recruiting
Research Site
Camden, New Jersey · Not yet recruiting
Research Site
The Bronx, New York · Not yet recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Blue Ash, Ohio · Recruiting
Research Site
Dayton, Ohio · Recruiting
Research Site
Sylvania, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
York, Pennsylvania · Not yet recruiting
Research Site
Germantown, Tennessee · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Tyler, Texas · Recruiting
Research Site
Salt Lake City, Utah · Withdrawn
Research Site
Fairfax, Virginia · Recruiting
Research Site
Roanoke, Virginia · Recruiting
Research Site
Seattle, Washington · Recruiting
Showing 40 of 299 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.